Immediate Press release Date February 3, 2025 — Kolkata, India Pushpanjali Eye Care, a leading eye care center in the region, is proud to announce the successful introduction of an innovative gene therapy for Retinitis Pigmentosa (RP) and Age-Related Macular Degeneration (AMD) under the expert guidance of Dr. Prashant Srivastava. This breakthrough therapy, designed to treat these debilitating retinal conditions, marks a significant advancement in the field of ophthalmology, offering new hope to patients suffering from progressive vision loss.Retinitis Pigmentosa (RP) and Age-Related Macular Degeneration (AMD) is directly affect retina. It is an eye disease which can spread genetically. It can usually spread in young people and affect peripheral vision initially. Pushpanjali Eye Care make an intiative for general awarness program for Retina Pigmentosa and AMD for general people. People may search best eye care hospital in Kolkata for treat their retina eye condition. Retinitis Pigmentosa (RP) and Age-Related Macular Degeneration (AMD) directly affect the retina. It is an eye disease which can spread genetically. It can usually spread in young people and affect peripheral vision initially. On the other hand, AMD is directly affected by central vision. Retinitis Pigmentosa, a rare genetic disorder, and Age-Related Macular Degeneration, a leading cause of vision loss in older adults, have long been challenging to treat. Both conditions affect the retina, leading to gradual vision impairment and, if left untreated, can result in permanent blindness. The new gene therapy aims to target the underlying genetic causes of these conditions, providing a potential long-term solution for patients who previously had limited treatment options. Revolutionary Approach to Treatment The therapy introduced at Pushpanjali Eye Care utilizes cutting-edge gene-editing technology to repair or replace faulty genes within the retina. This innovative treatment has the potential to slow, halt, or even reverse the damage caused by RP and AMD, significantly improving the quality of life for those affected. In contrast to traditional treatments that focus on managing symptoms, the new therapy directly addresses the root cause of retinal degeneration. Retina Treatment is required as soon as possible for initial treatment and cure of your eyes. “We are extremely excited about the potential of this gene therapy for treating Retinitis Pigmentosa and Age-Related Macular Degeneration,” said Dr. Prashant Srivastava, the renowned ophthalmologist at Pushpanjali Eye Care. “The therapy’s success in early trials has shown promising results in stabilizing vision and, in some cases, even improving retinal function. This breakthrough represents a major step forward in the fight against retinal diseases that have long been a challenge for both patients and healthcare providers.” How the Gene Therapy Works Gene therapy for Retinitis Pigmentosa and AMD works by introducing healthy copies of the defective genes into the retinal cells. This is done through a procedure called gene delivery, where a viral vector is used to carry the new genetic material directly into the affected retinal cells. Once the correct genes are in place, they can begin to produce the necessary proteins that are typically missing or malfunctioning in the retina, leading to improved vision. For patients with RP and AMD, this therapy offers the potential to preserve their vision for a longer period and, in some cases, restore partial sight. Early clinical trials have demonstrated encouraging results, with many patients reporting enhanced visual acuity and a reduction in the progression of their retinal disease. Pioneering Work at Pushpanjali Eye Care Pushpanjali Eye Care has been at the forefront of innovation in the field of eye care, continually incorporating the latest technologies and treatment methods to ensure the best outcomes for its patients. Under the leadership of Dr. Prashant Srivastava, the clinic has become a trusted name for those seeking advanced treatments for various retinal conditions. Dr. Srivastava, with years of experience in managing complex retinal diseases, has been instrumental in bringing this groundbreaking gene therapy to India. His deep expertise in retinal disorders, coupled with the clinic’s state-of-the-art facilities, has made Pushpanjali Eye Care one of the most sought-after centers for the treatment of RP, AMD, and other retinal diseases. The Future of Retinal Disease Treatment The introduction of gene therapy at Pushpanjali Eye Care is a pivotal moment in the treatment of retinal diseases. As research in gene therapy continues to evolve, it holds promise for providing new and more effective treatments for a variety of eye conditions, including other inherited retinal diseases. “The future of retinal disease treatment is incredibly exciting,” said Dr. Srivastava. “While there is still much research to be done, the success we have seen so far with gene therapy offers a glimpse into a world where patients with retinal diseases can look forward to a better quality of life, potentially without the fear of progressive blindness.” Pushpanjali Eye Care is committed to ensuring that patients have access to the best and most advanced treatments available. The clinic’s ongoing research and collaborations with international medical institutions further solidify its position as a leader in the field of eye care.

Visit: https://pushpanjalieyecare.com/